Glenmark Pharmaceuticals has announced that it will receive an unspecified amount up front, plus regulatory and commercial milestone payments, from Seqirus for the rights to commercialize Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray in Australia and New Zealand.
In December 2017, Glenmark announced positive results from a Phase 3 trial of Ryaltris for the treatment of seasonal allergic rhinitis, and the company filed an NDA for Ryaltris in the US in May 2018. Seqirus will take responsibility for regulatory filing in Australia and New Zealand.
Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha commented, “We are delighted to collaborate with Seqirus to commercialize Ryaltris in Australia and New Zealand. Seqirus’ strong presence in allergy in these markets makes them an ideal partner for Glenmark. The partnership is also in line with our strategy of launching Ryaltris across markets either directly or through partnerships making it our first global brand.”
Seqirus VP of Commercial Operations Lorna Meldrum said, “We are very excited to be working with Glenmark on the distribution, marketing and sales of their novel allergic rhinitis product upon approval. Ryaltris is an important addition to Seqirus’ growing product range and strengthens our broad portfolio of in-licensed medicines in Australia and New Zealand.”
Read the Glenmark Pharmaceuticals press release.
